Randomized controlled trial of single-agent glimepiride and pioglitazone in Japanese patients with type 2 diabetes: A comparative study (Q33603557)

28 July 2017

Randomized controlled trial of single-agent glimepiride and pioglitazone in Japanese patients with type 2 diabetes: A comparative study (English)

1 reference

28 July 2017

1 reference

Nobuya Inagaki

3

0 references

author name string

Nobuyuki Shihara

1

1 reference

28 July 2017

Masafumi Kitaoka

2

1 reference

28 July 2017

Takashi Kadowaki

4

1 reference

28 July 2017

Seisuke Koumoto

5

1 reference

28 July 2017

Jo Satoh

6

1 reference

28 July 2017

Yasuo Terauchi

7

1 reference

28 July 2017

Kiyohide Nunoi

8

1 reference

28 July 2017

Yuichiro Yamada

9

1 reference

28 July 2017

Hiroyuki Sakamaki

10

1 reference

28 July 2017

Yutaka Seino

11

1 reference

28 July 2017

1 October 2011

1 reference

Journal of Diabetes Investigation

28 July 2017

1 reference

28 July 2017

2

1 reference

28 July 2017

5

1 reference

28 July 2017

391-398

1 reference

Report of the committee on the classification and diagnostic criteria of diabetes mellitus

28 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019308

Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019308

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019308

10-year follow-up of intensive glucose control in type 2 diabetes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019308

Westernized-like-diet-fed rats: effect on glucose homeostasis, lipid profile, and adipocyte hormones and their modulation by rosiglitazone and glimepiride

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019308

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019308

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019308

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019308

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019308

Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019308

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019308

Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019308

Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: postmarketing surveillance study in Japan.

21 June 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00115.X

Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00115.X

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00115.X

Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00115.X

Glimepiride increases high-density lipoprotein cholesterol via increasing adiponectin levels in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00115.X

Glimepiride exhibits prophylactic effect on atherosclerosis in cholesterol-fed rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00115.X

10.1111/J.2040-1124.2011.00115.X

21 January 2018

Identifiers

DOI

0 references

PMCID

4019308

1 reference

28 July 2017

1 reference